MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Rosetta Genomics Company Profile (NASDAQ:ROSG)

Consensus Ratings for Rosetta Genomics (NASDAQ:ROSG) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.33 (192.40% upside)

Analysts' Ratings History for Rosetta Genomics (NASDAQ:ROSG)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016AegisReiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Barrington ResearchLower Price TargetOutperform$5.00 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Rosetta Genomics (NASDAQ:ROSG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/19/2016        
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.33)($0.14)$3.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.18)($0.18)($0.18)
Q2 20161($0.17)($0.17)($0.17)
Q3 20161($0.16)($0.16)($0.16)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)
Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
DateHeadline
06/24/16 06:17 PMRosetta Genomics Ltd. (NASDAQ:ROSG) Yearly Sales Target At $74.285 - Investor Newswire
06/24/16 06:17 PMRosetta Genomics Ltd. (USA) (NASDAQ:ROSG) Completes 50-State Sweep For Its FISH Tests - Scibility Media
06/23/16 08:49 AMRosetta Genomics (ROSG) Wins Conditional New York State Approval for HEME FISH-based Assays
06/23/16 08:49 AMRosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
06/23/16 08:49 AMBRIEF-Rosetta Genomics Ltd announces agreement with Preferred Provider Organization
06/23/16 08:49 AMRosetta Genomics USA : Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
06/22/16 12:01 PMRosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 -
06/22/16 10:54 AM8 Biggest Mid-Day Gainers For Tuesday - Benzinga
06/22/16 10:54 AMRosetta Genomics (ROSG) Wins Conditional New York State Approval for HEME FISH-based Assays - StreetInsider.com
06/22/16 10:54 AMLast Analysts Rating Review: Rosetta Genomics Ltd. (NASDAQ:ROSG) , Medtronic plc (NYSE:MDT) - Street Updates
06/21/16 10:29 AMRosetta Genomics Receives Approval from New York State for HEME FISH-based Assays
06/21/16 10:19 AMHere’s Why These Five Stocks Are Gaining Ground on Tuesday -
06/19/16 09:57 AMRosetta Genomics Ltd. (NASDAQ:ROSG) Yearly Sales Projections At $74.285 - Investor Newswire
06/17/16 08:54 AMEnvision Healthcare Holdings, Inc. (NYSE:EVHC) plummeted -6.18%: Rosetta Genomics, Ltd. (NASDAQ:ROSG ... - KC Register
06/11/16 06:21 PMCan Rosetta Genomics Ltd. (NASDAQ:ROSG) Keep Up with Analyst Expectations? - Investor Newswire
06/03/16 09:07 AMBroker Watchlist: Rosetta Genomics Ltd. (ROSG) - Share Trading News
05/26/16 11:59 PMRevenue Update on Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG) - Trade Calls - Revenue Update on Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG)Trade CallsRosetta Genomics Ltd. (USA)(NASDAQ:ROSG) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 19, 2016. Earnings per share were $-0.18. Rosetta Genomics Ltd. (USA) (ROSG) made into the ...Rosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay DataStreetInsider.comRosetta Genomics Reports Positive Data on Novel Thyroid Nodule Classification Test; Shares Flat Pre Bell (NASDAQ ...Sonoran Weekly Reviewall 3 news articles »
05/26/16 07:06 AMRosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay Data - StreetInsider.com - Rosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay DataStreetInsider.comRosetta Genomics Ltd. (Nasdaq: ROSG) announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, ...and more »
05/26/16 06:00 AMRosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company’s novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology.
05/25/16 10:19 AMLatest Analyst Ratings For Rosetta Genomics Ltd. (ROSG) - Share Trading News - Latest Analyst Ratings For Rosetta Genomics Ltd. (ROSG)Share Trading News03/28/2016 – Rosetta Genomics Ltd. had its “outperform” rating reiterated by analysts at Barrington Research. They now have a USD 3.5 price target on the stock. 03/24/2016 – Aegis Capital began new coverage on Rosetta Genomics Ltd. giving the company ...
05/23/16 11:53 AMRosetta Genomics (ROSG) Announces New York State Approval for Four PCR-Based Assays - StreetInsider.com - Rosetta Genomics (ROSG) Announces New York State Approval for Four PCR-Based AssaysStreetInsider.comRosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the ...and more »
05/23/16 07:05 AM8:05 am Rosetta Genomics receives conditional approval from the NY State Department of Health for four allele-specific PCR (CAST PCR)-based assays -
05/23/16 07:00 AMRosetta Genomics Receives Approval from New York State for Four PCR-Based Assays - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health for the Company’s allele-specific PCR -based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers.
05/19/16 11:53 PMRosetta Genomics USA : Reports 2016 First Quarter Financial Results - 02:05p ROSETTA GENOMICS USA: Reports 2016 First Quarter Financial Results 05/16 ROSETTA GENOMICS USA: to Host 2016 First Quarter Financial Results and Business.. 03/23 ROSETTA GENOMICS USA: Reports 2015 Full Year Financial Results 03/17 ROSETTA GENOMICS ...
05/19/16 02:41 PMEdited Transcript of ROSG earnings conference call or presentation 19-May-16 2:00pm GMT -
05/19/16 10:02 AMRosetta Genomics Reports 2016 First Quarter Results - [at noodls] - c351f672-b264-4de6-97c6-3ed334884085.pdf News Release Rosetta Genomics Reports 2016 First Quarter Financial Results Record Quarterly Clinical Testing Revenues of $2.6 million Conference call begins today ...
05/19/16 07:00 AMRosetta Genomics Reports 2016 First Quarter Financial Results - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.
05/19/16 06:07 AMQ1 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open -
05/18/16 06:42 PMRosetta Genomics Ltd. (NASDAQ:ROSG) To Release Earnings On Thursday - Share Trading News - Rosetta Genomics Ltd. (NASDAQ:ROSG) To Release Earnings On ThursdayShare Trading NewsAt the moment 4 analysts are watching Rosetta Genomics Ltd. (NASDAQ:ROSG), 0 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”. Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 3.81 million.
05/16/16 01:22 PMRosetta Genomics to Host 2016 First Quarter Financial and Business Update Conference Call on May 19, 2016 - [at noodls] - f22d8f3d-4f8b-45a6-97d3-85bb5e53a08f.pdf News Release Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016 PHILADELPHIA, PA. and REHOVOT, Israel ...
05/16/16 07:00 AMRosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016 - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S.
05/14/16 12:08 AMRosetta Genomics Ltd. (NASDAQ:ROSG) Latest Impact Score At 0 - Stocks Daily - Rosetta Genomics Ltd. (NASDAQ:ROSG) Latest Impact Score At 0Stocks DailyRosetta Genomics Ltd. (NASDAQ:ROSG) has a -0.217 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on ...and more »
05/02/16 07:49 PMBroker Outlook For The Week Ahead: Rosetta Genomics Ltd. (ROSG) - Share Trading News - Broker Outlook For The Week Ahead: Rosetta Genomics Ltd. (ROSG)Share Trading News02/23/2015 – Rosetta Genomics Ltd. had its “outperform” rating reiterated by analysts at Zacks. They now have a USD 10.5 price target on the stock. The share price of Rosetta Genomics Ltd. (ROSG) was down -1.50% during the last trading session, with a ...and more »
04/28/16 07:30 PMRosetta Genomics Ltd. (ROSG) Updated Broker Price Targets - Share Trading News - Rosetta Genomics Ltd. (ROSG) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Rosetta Genomics Ltd. (ROSG). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...
04/27/16 07:13 PMRosetta Genomics Ltd. (ROSG) Updated Analyst Coverage - Risers & Fallers - Rosetta Genomics Ltd. (ROSG) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Rosetta Genomics Ltd. (ROSG). According to the latest broker reports outstanding on Wednesday 27th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
04/24/16 08:40 PMNext Weeks Broker Price Targets For Rosetta Genomics Ltd. (ROSG) - Share Trading News - Next Weeks Broker Price Targets For Rosetta Genomics Ltd. (ROSG)Share Trading NewsRosetta Genomics Ltd. has a 50 day moving average of 1.26 and a 200 day moving average of 1.39. The stock's market capitalization is 19.15M, it has a 52-week low of 0.71 and a 52-week high of 4.13. The share price of the company (ROSG) was down ...
04/22/16 07:32 PMBroker Roundup For Rosetta Genomics Ltd. (ROSG) - Share Trading News - Broker Roundup For Rosetta Genomics Ltd. (ROSG)Share Trading News02/23/2015 – Rosetta Genomics Ltd. had its “outperform” rating reiterated by analysts at Zacks. They now have a USD 10.5 price target on the stock. The share price of Rosetta Genomics Ltd. (ROSG) was up +2.27% during the last trading session, with a ...and more »
04/16/16 01:08 AMGlobal Demand for Personalized Medicines Market - The leading players competing in personalized medicines market are Bayer HealthCare Pharmaceuticals, Abbott Molecular, Inc., Celera Diagnostics, Hologic, Inc., Rosetta Genomics Ltd., Macrogen, Inc., IRIS Personalized Medicine, Bristol-Myers Squibb ...
04/15/16 07:28 PMSales Of $71.625 Is Expected For Rosetta Genomics Ltd. (NASDAQ:ROSG) - Stocks Daily - Sales Of $71.625 Is Expected For Rosetta Genomics Ltd. (NASDAQ:ROSG)Stocks DailyThe mean of the annual revenue estimate of Rosetta Genomics Ltd. (NASDAQ:ROSG) is $71.625 and the median is $71.625 as anticipated by 2 analysts for the period ended 4. The highest estimate is set at $105 while lowest projection stands at $38.25.
04/13/16 08:35 AMRosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2015 By the Numbers -
04/13/16 08:01 AMRosetta Genomics Ltd. :ROSG-US: Earnings Analysis: 2015 By the Numbers -
04/12/16 07:53 PMNew Analyst Ratings On Rosetta Genomics Ltd. (ROSG) - Risers & Fallers - New Analyst Ratings On Rosetta Genomics Ltd. (ROSG)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Rosetta Genomics Ltd. (ROSG). The latest broker reports which are currently outstanding on Tuesday 12th of April state 0 analysts have a rating of “strong buy”, 4 analysts ...
04/11/16 11:14 AMBusiness People on the Move: Brian Zoubek hired by Philadelphia firm - She had been COO for Prospect Mortgage. Rosetta Genomics Ltd., a diagnostic test developer based in Israel and Philadelphia, has hired Ana C. Ward as executive vice president, legal and corporate development. She had been COO of Aptamir Therapeutics.
04/10/16 11:57 PMBusiness People on the Move: Brian Zoubek hired as investment sales and leasing specialist - She had been COO for Prospect Mortgage. Rosetta Genomics Ltd., a diagnostic test developer based in Israel and Philadelphia, has hired Ana C. Ward as executive vice president, legal and corporate development. She had been COO of Aptamir Therapeutics.
04/10/16 11:53 AMBroker Outlook For The Week Ahead Rosetta Genomics Ltd. (ROSG) - Share Trading News - Broker Outlook For The Week Ahead Rosetta Genomics Ltd. (ROSG)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Rosetta Genomics Ltd. (ROSG). The most recent broker reports which have been released note that 0 analysts have a ...and more »
04/09/16 06:37 PMRosetta Genomics Limited Ord (NASDAQ:ROSG) Shorted Shares Increased 32.18% After Market Selling - Clinton Financial - Rosetta Genomics Limited Ord (NASDAQ:ROSG) Shorted Shares Increased 32.18% After Market SellingClinton FinancialThe stock of Rosetta Genomics Limited Ord (NASDAQ:ROSG) registered an increase of 32.18% in short interest. ROSG's total short interest was 770,200 shares in April as published by FINRA. Its up 32.18% from 582,700 shares, reported previously.
02/25/16 08:00 AMRosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of Three New Product Offerings - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces the launch of three high-value molecular diagnostic offerings in order to better serve current and prospective clients with a broader molecular test menu.
02/18/16 08:00 AMRosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid Fine Needle Aspirate smears from the New York State Department of Health under the Company’s Molecular Oncology permit.
02/08/16 07:00 AMRosetta Genomics to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Source Capital’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City.
02/01/16 01:22 PMRosetta Genomics Announces Agreement with America’s Choice Provider Network for Entire Suite of Diagnostic Tests and Services - [at noodls] - 31c802c0-b941-473e-bfb5-1beec5d83534.pdf News Release Rosetta Genomics Announces Agreement with America's Choice Provider Network for Entire Suite of Diagnostic Tests and Services Provides access to more ...
About Rosetta Genomics

Rosetta Genomics logoRosetta Genomics Ltd. is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has developed platform technologies for the identification, extraction, quantification and analysis of microRNAs from a range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects in cancer, cardiovascular diseases and other indications. The Company's four commercial oncology tests have been launched in multiple countries across the world. The Company is working to develop additional tests in the cancer realm and in other fields. It is marketing and selling the four diagnostic tests based on its microRNA technologies, which include Rosetta Cancer Origin Test, Rosetta Lung Cancer Test, Rosetta Kidney Cancer Test and Rosetta Mesothelioma Test. The Company's therapeutic pipeline consists of the projects, such as CMV Therapeutic and Rimonim Consortium.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ROSG
  • CUSIP:
Key Metrics:
  • Previous Close: $1.14
  • 50 Day Moving Average: $1.15
  • 200 Day Moving Average: $1.14
  • P/E Ratio: N/A
  • P/E Growth: -0.12
  • Market Cap: $23.77M
  • Current Quarter EPS Consensus Estimate: $-0.65 EPS
Additional Links:
Rosetta Genomics (NASDAQ:ROSG) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha